参贝支扩片联合常规治疗对支气管扩张患者的临床疗效  

Clinical effects of Shenbei Zhikuo Tablets combined with routine treatment on bronchiectasis patients

作　　者：吴文飞[1] 李玉平[1] 李俊[1] 韩明权[1] WU Wen-fei;LI Yu-ping;LI Jun;HAN Ming-quan(Shanghai Pulmonary Hospital Affiliated to Tongji University,Shanghai 200433,China)

机构地区：[1]同济大学附属上海市肺科医院,上海200433

出　　处：《中成药》2019年第4期808-814,共7页Chinese Traditional Patent Medicine

摘　　要：目的探讨参贝支扩片联合常规治疗对支气管扩张患者的临床疗效。方法 129例患者随机分为对照组(64例)和观察组(65例),对照组给予常规治疗,观察组在对照组基础上加用参贝支扩片,28 d为1个疗程。然后,通过积分评估法、四级标准法、视觉模拟评分(VAS)法评价临床疗效。结果与对照组比较,观察组主症评分、积分、疗效指标,中医证候疗效指标,VAS评价指标显著改善(P<0.01),有效率显著提高(P<0.01),不良事件发生率无明显变化(P>0.05)。结论参贝支扩片联合常规治疗对支气管扩张患者临床疗效良好,安全性较高。AIM To explore the clinical effects of Shenbei Zhikuo Tablets combined with routine treatment on bronchiectasis patients.METHODS One hundred and twenty-nine patients were randomly divided into control group(64 cases)and observation group(65 cases),the control group was given routine treatment,while the observation group was added with Shenbei Zhikuo Tablets on the basis of the control group,28 days as a course of treatment.Subsequently,integral assessment,four-grade standard and visual analogue scale(VAS)methods were used to evaluate clinical efficacy.RESULTS Compared with the control group,the observation group demonstrated significantly improved main symptom score,integral,efficacy indices and TCM syndrome efficacy indices(P<0.01),and markedly increased effective rate(P<0.01),with no obvious change in the occurrence rate of adverse events(P>0.05).CONCLUSION For the bronchiectasis patients,Shenbei Zhikuo Tablets combined with routine treatment exhibits good clinical efficacy and high safety.

关 键 词：参贝支扩片 常规治疗 支气管扩张 

分 类 号：R287[医药卫生—中药学]